Agoracom Blog Home

Archive for the ‘Empower Clinics Inc.’ Category

EMPOWER CLINICS ANNOUNCES AWARD OF FIRST CLINICAL TRIAL FROM GLOBAL FORTUNE 500 PHARMACEUTICAL COMPANY

Posted by Aidi Munoz at 9:40 AM on Tuesday, September 26th, 2023

Empower Clinics Inc (EPW: CSE) (EPWCF: PINK), a leading healthcare company, is proud to announce a significant milestone in its research and clinical trials division. Its subsidiary, EPW Curesearch LLC (“EPWC”), has successfully secured its inaugural clinical trial from a major European pharmaceutical powerhouse with a staggering market capitalization exceeding $100 billion. This monumental achievement is set to impact the future of healthcare outcomes worldwide.

Building upon its previous announcement on July 31, 2023, which highlighted multiple study applications covering diverse disease states, Empower Clinics confirms that this awarded clinical trial will be dedicated to addressing Chronic Obstructive Pulmonary Disease (COPD). The trial will be spearheaded by one of the company’s most seasoned Principal Investigators (PIs).

The collaboration between Empower Clinics, their PI, and the pharmaceutical sponsor is poised to enroll between 20 to 35 patients, primarily from the existing patient roster, with the recruitment window extending into mid-2024 and the possibility of extensions. Remarkably, there are no restrictions on the maximum number of patients per site, enabling EPWC to source additional participants from external medical centers, hospitals, and various social recruitment channels, including Facebook, Instagram, Twitter, and other digital marketing avenues.

Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm, stating, “We are all ecstatic to receive our first awarded clinical trial, a result of consistent and persistent effort over the past number of months. Our focus on partnering with large established medical centers and very experienced medical doctors has proven successful.” He further anticipates additional sponsor due diligence, site visits, and awards in the future.

Empower Clinics has strategically aligned itself with practicing medical doctors, who are specialists in their respective fields and have previous research and clinical trials experience. These PIs play a pivotal role in the success of Empower’s Site Management Organization (SMO), facilitating meaningful revenues from the Biotech and Pharmaceutical industries, providing oversight and support to patients, and acting as a crucial liaison between pharmaceutical companies and Contract Research Organizations (CROs).

While the company continues to navigate through a Cease Trade Order and accounting and audit procedures, the enormous market opportunity beckons. The Clinical Research Organization (CRO) Services Market is set to reach $127.3 billion by 2028, driven by the ever-expanding pharmaceutical, biotechnology, and medical device R&D pipelines, as well as advancements in clinical trial processes. Empower Clinics is positioned to play a pivotal role in this transformative era of healthcare.

About Empower:

Empower is a patient-focused healthcare company committed to making a positive impact on lives and future healthcare outcomes through clinical trials. With two clinical research sites and six principal investigators, Empower operates as a Site Management Organization (SMO) with multiple clinical trials in the pipeline. Additionally, the company has announced its intention to create a healthcare AI spinout focused on enhancing patient identification, recruitment, and onboarding for clinical trials.

Read release: https://www.einpresswire.com/article/657704521/empower-clinics-announces-award-of-first-clinical-trial-from-global-fortune-500-pharmaceutical-company

VIDEO – Empower Clinics Proposes Spin Out As Growth Of Research and Clinical Trials Accelerates With Multiple Clinical Study Applications

Posted by Aidi Munoz at 4:55 PM on Thursday, August 3rd, 2023

Empower Clinics Proposes Spin Out As Growth Of Research and Clinical Trials Accelerates With Multiple Clinical Study Applications From Pharmaceutical Companies.

In a recent press release, Empower Clinics Inc. (CSE: EPW) (OTC: EPWCF) announced its proposal for a division spin-out and a strategic move towards the healthcare artificial intelligence (AI) sector. After a thorough strategic review, the company intends to complete a direct spin-out of its wholly-owned subsidiary, “Subco,” and simultaneously acquire a healthcare AI technology or service company.

In this exclusive interview, Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm about this strategic move. He highlighted that this spin-out and focus on healthcare AI as a separate entity would unlock significant shareholder value and provide clarity to investors regarding each company’s direction.

Regarding the Target, McAuley discussed the potential impact of AI and machine learning in the healthcare sector, particularly in patient recruitment for clinical trials. Empower’s expertise in research and clinical trials uniquely positions them to understand the significance of AI in drug development. By applying AI algorithms to patient rosters and data, the industry can significantly improve patient recruitment speed, accuracy, and overall success rates in new drug development.

Overall, this strategic move by Empower Clinics marks a promising step into the fast-growing healthcare AI sector and represents an exciting opportunity for shareholders and investors alike. As developments unfold, investors are encouraged to stay informed about the company’s progress in this transformative endeavor.

Now sit back relax and watch this powerful interview with Steven McAuley, Chairman & CEO of Empower Clinics.

VIDEO – Empower Clinics CERES Initiative Full Steam Ahead To Manage 1.2M Passengers 2022. More Chess Moves Reveal US Clinic and NASDAQ Goals

Posted by AGORACOM-JC at 11:42 AM on Tuesday, February 22nd, 2022
Epw logo1

Empower Clinics CEO Steve McAuley took questions from shareholders and provided a powerful update on the following topics:

  • Partnership With CERES Terminals Canada. Scope of Work & Revenue Mode
  • Status Of Clinics Acquisitions – Imminent Closin
  • Appointment Of Healthcare Powerhouse Anthony Tomasello To The Board
    • What His Appointment Means For US Expansion and NASDAQ Goal
  • Appointment Of Carolyn Shields As SVP Of Clinics Operations
    • What Her Appointment Means For Clinics Expansion In 202
  • New Clinic Openings – Next Ribbon Cutting Soon With Steve Attending For Shareholder “Town Hall” Meeting

As always we want to thank shareholders for taking the time to submit great questions.

VIDEO – Empower Clinics Q3-21 Revenue Up 372% YOY, Further Clinic Expansion Under Way

Posted by AGORACOM-JC at 4:37 PM on Monday, November 29th, 2021

Nine-month year-over-year revenue growth of 1,349% 

Empower Clinics continues to fire on all cylinders. This is evident by the strong Q3 results that the company released last week. 

Steven McAuley, Chairman and CEO of Empower commented: 

“This quarter marked the start of a new chapter for the Company and the Empower team. We launched The Medi-Collective brand and clinics, expanded Kai Labs’ facilities and completed the acquisition of MediSure. Each of these milestones is an intrinsic aspect of our strategic growth vision. 

Key Q3-2021 Highlights

  • Revenue from continuing operations of $405,707 compared to $85,960 in Q3 2020, representing 372% year-over-year growth.
  • Revenue from continuing operations of $3,226,335 for nine months YTD 2021 compared to $222,690 for nine months YTD 2020, representing 1,349% year over year growth.

What does CEO Steven McAuley think of these results?

“With positive year-over-year growth coming out of this quarter, we will maximize our fully operational divisions’ capabilities and reach across Canada and the U.S. I’m encouraged by our partnerships and acquisitions progress into Q4 2021 and look forward to the coming months.”

Sit back, relax and watch this powerful interview.

VIDEO – With First New Clinic Launches In Ontario Imminent, Empower Clinics Is Sitting On A Launchpad That Will Keep The Company Flying Through 2022 And Beyond

Posted by AGORACOM-JC at 4:04 PM on Monday, August 16th, 2021

In an interview just over a month ago, Empower Clinics CEO Steve McAuley talked about how the Company is in full-blown growth mode that were best summarized as follows:

“Multiple opportunities have been percolating and I’m going to turn up the heat”

To this added seeing 

“substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.

Today McAuley and the team at Empower backed up those words with this announcement:

“The Company can now confirm the first new clinic launches will take place in September – location and ribbon cutting ceremonies to be announced – with rollouts of further locations continuing on a regular basis from that point forward.”

In today’s interview McAuley takes shareholders through a detailed overview of the foundation that has now been built, ready to launch and strong enough to catapult Empower into a completely new orbit.
Watch this great interview.  Welcome to the launch pad.   

VIDEO – With 2020 Audit Complete, Empower Clinics CEO Steve McAuley Sees Big Growth For Operations, US Expansion, Market Cap & Uplisting

Posted by AGORACOM-JC at 6:17 PM on Monday, July 5th, 2021

With $US 3.2M in 2020 revenue, representing a 58% increase over the previous year, you would think Empower Clinics CEO Steve McAuley would use his first interview after the filing to celebrate. 

He isn’t. 

Rather, with Fiscal 2020 having come to end more than 6 months ago, the 2020 results are a distant rear view mirror shot of a Company that is in full-blown growth mode and can be best summarized as follows: 

“Multiple opportunities have been percolating and I’m going to turn up the heat” 

To this end McAuley sees a “substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”. 

We could try to list all the powerful things he had to say in this interview – but best we let you watch/hear it straight from Steve in this amazing interview. 

VIDEO – Empower Clinics $CBDT.ca $EPWCF In Advanced Discussions With Large US Pharmacies As Proposed Acquisition Includes Products In 4,000 Canadian Pharmacies $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:57 PM on Thursday, June 3rd, 2021

As if today’s press release wasn’t good enough Empower Clinics Announces Major Expansion with Proposed Acquisition of Medisure Canada. Diabetes Tests and Devices Carried In 4,000 Pharmacies and Generated $1.9m in 2020 Revenue, shareholders also received this injection of confidence from CEO

Steve McAuley:

“As I’ve stated to our shareholders on multiple occasions throughout 2021, Empower is in the strongest position it has ever been and will continue to grow every aspect of our business unabated and without interruption. In addition to this acquisition, in the last 30 days alone we have announced expansions of our clinics, gone live on our KAI Saliva RT-PCR test with Air Canada and are very advanced on tripling the size of the KAI Medical Laboratory facility. We are hitting on all cylinders and well on our way to becoming a major vertically integrated healthcare company. I fully expect Empower to have continued strong business announcements in June and throughout 2021″

If that was all, it would be a great day … and it was with $CBDT closing up 16.5% on 7.5M shares to $0.53 … but then Steve shared some powerful information about leveraging this acquisition with large US pharmacies.  

Who did he name? 

Watch this great interview with CEO Steve McAuley.

VIDEO – Empower Clinics $CBDT.ca $EPWCF Shareholder Q&A With CEO Steve McAuley – Part 1 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:23 PM on Friday, May 7th, 2021

PART 1 of Empower Clinics Shareholder Q&A with CEO Steve McAuley.

Topics Covered:

  • Annual Financials
  • KAI Labs
  • Clinics / Rexall
  • KAI Saliva
  • Pipelines

Part 2 next week.

VIDEO – Watch Our Latest Shareholder Q&A With @EmpowerClinics $CBDT $EPWCF

Posted by AGORACOM-JC at 9:06 PM on Thursday, April 15th, 2021

Empower $CBDT.ca $EPWCF Announces DTC Eligibility $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:16 AM on Thursday, April 15th, 2021
  • Company Stock Is Now More Accessible to U.S. Investors
  • United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).

VANCOUVER B.C. / April 15, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTC PINK:EPWCF) (“Empower” or the “Company”) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – is pleased to announce it is now eligible for Depository Trust Company (“DTC”) services in relation to Empower’s listing on the OTC.

United States investors may now more easily trade Empower’s OTC stock (OTC PINK:EPWCF) in addition to Empower’s listing on the CSE (CSE:CBDT) and (FRA:8EC).

“Convenience is a core part of Empower’s overall strategy for our approach to integrated healthcare, so our capital markets strategy should be the same. I’m thrilled that trading Empower’s shares will now be easier for existing and potential shareholders in the U.S.,” said Steven McAuley, Chairman & CEO of Empower. “Empower has a strong and growing presence in the United States market operationally as well as for investors. We’re confident that we will see enhanced trading liquidity as a result of our DTC eligibility.”

DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages the electronic clearing and settlement of publicly traded companies. Empower is now eligible to be electronically cleared and settled through the DTC and is therefore considered “DTC eligible”. This electronic method of clearing securities streamlines the process of trading, enhances liquidity, and provides direct access to investors and brokers in the U.S. OTC capital markets.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics